ECSP21075073A - Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos - Google Patents

Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos

Info

Publication number
ECSP21075073A
ECSP21075073A ECSENADI202175073A ECDI202175073A ECSP21075073A EC SP21075073 A ECSP21075073 A EC SP21075073A EC SENADI202175073 A ECSENADI202175073 A EC SENADI202175073A EC DI202175073 A ECDI202175073 A EC DI202175073A EC SP21075073 A ECSP21075073 A EC SP21075073A
Authority
EC
Ecuador
Prior art keywords
cancer
compositions
treatment
methods
psychoactive effects
Prior art date
Application number
ECSENADI202175073A
Other languages
English (en)
Inventor
Jay E Moon
Original Assignee
Powderpost Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72751285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21075073(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Powderpost Llc filed Critical Powderpost Llc
Publication of ECSP21075073A publication Critical patent/ECSP21075073A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Algunas realizaciones incluyen una metodología de administración de cannabinoides. En algunas realizaciones, uno o más cannabinoides tales como tetrahidrocannabinol (THC) y / o cannabidiol (CBD) se administran a través de un supositorio rectal o vaginal, o por vía intravenosa, no son psicoactivos. En algunos casos, el THC y / o CBD no son psicoactivos solo cuando se administran de la manera antes mencionada.
ECSENADI202175073A 2019-04-09 2021-10-12 Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos ECSP21075073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831534P 2019-04-09 2019-04-09
PCT/US2019/062979 WO2020209902A1 (en) 2019-04-09 2019-11-25 Methods and compositions for use in treatment of cancer without psychoactive effects

Publications (1)

Publication Number Publication Date
ECSP21075073A true ECSP21075073A (es) 2022-03-31

Family

ID=72751285

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202175073A ECSP21075073A (es) 2019-04-09 2021-10-12 Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos

Country Status (9)

Country Link
US (1) US20220168238A1 (es)
EP (1) EP3952860A1 (es)
BR (1) BR112021020302A2 (es)
CA (1) CA3136607A1 (es)
CL (1) CL2021002646A1 (es)
CO (1) CO2021013455A2 (es)
EC (1) ECSP21075073A (es)
MX (1) MX2021012400A (es)
WO (1) WO2020209902A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000031379A1 (it) 2020-12-18 2022-06-18 Curaleaf International Ltd Formulazione farmaceutica topica e metodo per il trattamento delle sindromi associate a dolore pelvico cronico
US20240049760A1 (en) * 2020-12-24 2024-02-15 Petro Pawlo Czupiel Safe-to-ingest microemulsions and nanoemulsions containing lipophilic components
WO2022144897A1 (en) * 2020-12-31 2022-07-07 Cannamore Biotechs Ltd. A composition for use in the treatment of rectal and/or intestinal inflammation
WO2022165439A1 (en) * 2021-02-01 2022-08-04 Aion Therapeutic Inc. Methods for treatment of human cancers using cannabis compositions
WO2023287742A1 (en) * 2021-07-12 2023-01-19 Integrative Therapy Discovery Lab S.R.L. Use of phytocannabinoids for treating endometrial cancer and endometriosis
AU2022376836A1 (en) 2021-10-26 2024-05-23 Dove Innovation Pty Limited Methods of treating head and neck cancers with hemp extract
EP4422769A2 (en) 2021-10-26 2024-09-04 Ecofibre USA Inc. Systems and methods for producing hemp extracts and compositions
CA3235074A1 (en) 2021-10-26 2023-05-04 Alexandra M CAPANO Methods of treating ovarian cancer with hemp extract
IL312245A (en) 2021-10-26 2024-06-01 Ecofibre Usa Inc Methods of treating endometriosis and other non-cancerous gynecological disorders with hemp extract
WO2023235833A1 (en) * 2022-06-03 2023-12-07 Pctrx, Inc. Polycannabinoid compositions and uses thereof
EP4608426A1 (en) 2022-10-26 2025-09-03 Ecofibre USA Inc. Stabilized compositions comprising cannabidiol
IL320517A (en) 2022-10-26 2025-06-01 Ecofibre Usa Inc Methods for treating estrogen-sensitive diseases with cannabis extract

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032158T2 (en) * 2008-10-31 2017-09-28 Univ Mississippi Process for the preparation of delta9-THC amino acid esters
WO2013009928A1 (en) * 2011-07-11 2013-01-17 Organic Medical Research Cannabinoid formulations
CA2952335A1 (en) * 2015-12-19 2017-06-19 Delta 9 Gardening B.V. Therapeutic delivery formulations and systems comprising cannabinoids and terpenes
WO2019195943A1 (en) * 2018-04-13 2019-10-17 Urban Juve Provisions Inc. Cannabis root extract, method of manufacture, method of use

Also Published As

Publication number Publication date
US20220168238A1 (en) 2022-06-02
CO2021013455A2 (es) 2022-01-17
BR112021020302A2 (pt) 2021-12-28
WO2020209902A1 (en) 2020-10-15
EP3952860A1 (en) 2022-02-16
CA3136607A1 (en) 2020-10-15
CL2021002646A1 (es) 2022-04-29
MX2021012400A (es) 2022-05-25

Similar Documents

Publication Publication Date Title
ECSP21075073A (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicoactivos
CO2019013887A2 (es) Composiciones y tratamientos para el trastorno del sueño
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
PE20200677A1 (es) Composicion de cannabis
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
AR080454A1 (es) Fitocanabinoides en el tratamiento del cancer
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
PE20200726A1 (es) Composicion de cannabis
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
MX383835B (es) Uso de cannabidiol en el tratamiento del complejo de escleroris tuberosa.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
CL2017001943A1 (es) Terapias de combinación para el tratamiento de cánceres
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
CL2017002998A1 (es) Plantas que tienen expresión modificada de thca sintasa
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
CO6290695A2 (es) Uso de canabinoides en combinación con un medicamento antisicótico.
MY156444A (en) Anti-tumoural effects of cannabinoid combinations
AR087842A1 (es) Fitocanabinoides que pueden usarse en el tratamiento del cancer
CO6341551A2 (es) Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion)
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
AR119043A1 (es) Métodos para acelerar la cicatrización mediante el uso de composiciones cannabinoides